BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

798 related articles for article (PubMed ID: 18041758)

  • 1. Crystallographic and computational studies on 4-phenyl-N-(beta-D-glucopyranosyl)-1H-1,2,3-triazole-1-acetamide, an inhibitor of glycogen phosphorylase: comparison with alpha-D-glucose, N-acetyl-beta-D-glucopyranosylamine and N-benzoyl-N'-beta-D-glucopyranosyl urea binding.
    Alexacou KM; Hayes JM; Tiraidis C; Zographos SE; Leonidas DD; Chrysina ED; Archontis G; Oikonomakos NG; Paul JV; Varghese B; Loganathan D
    Proteins; 2008 May; 71(3):1307-23. PubMed ID: 18041758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystallographic studies on N-azidoacetyl-beta-D-glucopyranosylamine, an inhibitor of glycogen phosphorylase: comparison with N-acetyl-beta-D-glucopyranosylamine.
    Petsalakis EI; Chrysina ED; Tiraidis C; Hadjiloi T; Leonidas DD; Oikonomakos NG; Aich U; Varghese B; Loganathan D
    Bioorg Med Chem; 2006 Aug; 14(15):5316-24. PubMed ID: 16616506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystallographic studies on two bioisosteric analogues, N-acetyl-beta-D-glucopyranosylamine and N-trifluoroacetyl-beta-D-glucopyranosylamine, potent inhibitors of muscle glycogen phosphorylase.
    Anagnostou E; Kosmopoulou MN; Chrysina ED; Leonidas DD; Hadjiloi T; Tiraidis C; Zographos SE; Györgydeák Z; Somsák L; Docsa T; Gergely P; Kolisis FN; Oikonomakos NG
    Bioorg Med Chem; 2006 Jan; 14(1):181-9. PubMed ID: 16213146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1-(3-Deoxy-3-fluoro-beta-d-glucopyranosyl) pyrimidine derivatives as inhibitors of glycogen phosphorylase b: Kinetic, crystallographic and modelling studies.
    Tsirkone VG; Tsoukala E; Lamprakis C; Manta S; Hayes JM; Skamnaki VT; Drakou C; Zographos SE; Komiotis D; Leonidas DD
    Bioorg Med Chem; 2010 May; 18(10):3413-25. PubMed ID: 20430629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic and crystallographic studies of glucopyranose spirohydantoin and glucopyranosylamine analogs inhibitors of glycogen phosphorylase.
    Watson KA; Chrysina ED; Tsitsanou KE; Zographos SE; Archontis G; Fleet GW; Oikonomakos NG
    Proteins; 2005 Dec; 61(4):966-83. PubMed ID: 16222658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of beta-D-glucopyranosyl bismethoxyphosphoramidate to glycogen phosphorylase b: kinetic and crystallographic studies.
    Chrysina ED; Kosmopoulou MN; Kardakaris R; Bischler N; Leonidas DD; Kannan T; Loganathan D; Oikonomakos NG
    Bioorg Med Chem; 2005 Feb; 13(3):765-72. PubMed ID: 15653344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of oxalyl derivatives of beta-d-glucopyranosylamine to muscle glycogen phosphorylase b.
    Hadjiloi T; Tiraidis C; Chrysina ED; Leonidas DD; Oikonomakos NG; Tsipos P; Gimisis T
    Bioorg Med Chem; 2006 Jun; 14(11):3872-82. PubMed ID: 16464598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose analogue inhibitors of glycogen phosphorylase: from crystallographic analysis to drug prediction using GRID force-field and GOLPE variable selection.
    Watson KA; Mitchell EP; Johnson LN; Cruciani G; Son JC; Bichard CJ; Fleet GW; Oikonomakos NG; Kontou M; Zographos SE
    Acta Crystallogr D Biol Crystallogr; 1995 Jul; 51(Pt 4):458-72. PubMed ID: 15299833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of N-acetyl-N '-beta-D-glucopyranosyl urea and N-benzoyl-N '-beta-D-glucopyranosyl urea to glycogen phosphorylase b: kinetic and crystallographic studies.
    Oikonomakos NG; Kosmopoulou M; Zographos SE; Leonidas DD; Chrysina ED; Somsák L; Nagy V; Praly JP; Docsa T; Tóth B; Gergely P
    Eur J Biochem; 2002 Mar; 269(6):1684-96. PubMed ID: 11895439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-(4-Substituted-benzoyl)-N'-(β-d-glucopyranosyl)ureas as inhibitors of glycogen phosphorylase: Synthesis and evaluation by kinetic, crystallographic, and molecular modelling methods.
    Nagy V; Felföldi N; Kónya B; Praly JP; Docsa T; Gergely P; Chrysina ED; Tiraidis C; Kosmopoulou MN; Alexacou KM; Konstantakaki M; Leonidas DD; Zographos SE; Oikonomakos NG; Kozmon S; Tvaroška I; Somsák L
    Bioorg Med Chem; 2012 Mar; 20(5):1801-16. PubMed ID: 22325154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarbo xylate.
    Oikonomakos NG; Tsitsanou KE; Zographos SE; Skamnaki VT; Goldmann S; Bischoff H
    Protein Sci; 1999 Oct; 8(10):1930-45. PubMed ID: 10548038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sourcing the affinity of flavonoids for the glycogen phosphorylase inhibitor site via crystallography, kinetics and QM/MM-PBSA binding studies: comparison of chrysin and flavopiridol.
    Tsitsanou KE; Hayes JM; Keramioti M; Mamais M; Oikonomakos NG; Kato A; Leonidas DD; Zographos SE
    Food Chem Toxicol; 2013 Nov; 61():14-27. PubMed ID: 23279842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The binding of β-d-glucopyranosyl-thiosemicarbazone derivatives to glycogen phosphorylase: A new class of inhibitors.
    Alexacou KM; Tenchiu Deleanu AC; Chrysina ED; Charavgi MD; Kostas ID; Zographos SE; Oikonomakos NG; Leonidas DD
    Bioorg Med Chem; 2010 Nov; 18(22):7911-22. PubMed ID: 20947361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ternary complex crystal structures of glycogen phosphorylase with the transition state analogue nojirimycin tetrazole and phosphate in the T and R states.
    Mitchell EP; Withers SG; Ermert P; Vasella AT; Garman EF; Oikonomakos NG; Johnson LN
    Biochemistry; 1996 Jun; 35(23):7341-55. PubMed ID: 8652510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycogen phosphorylase inhibitors: a free energy perturbation analysis of glucopyranose spirohydantoin analogues.
    Archontis G; Watson KA; Xie Q; Andreou G; Chrysina ED; Zographos SE; Oikonomakos NG; Karplus M
    Proteins; 2005 Dec; 61(4):984-98. PubMed ID: 16245298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose-based spiro-isoxazolines: a new family of potent glycogen phosphorylase inhibitors.
    Benltifa M; Hayes JM; Vidal S; Gueyrard D; Goekjian PG; Praly JP; Kizilis G; Tiraidis C; Alexacou KM; Chrysina ED; Zographos SE; Leonidas DD; Archontis G; Oikonomakos NG
    Bioorg Med Chem; 2009 Oct; 17(20):7368-80. PubMed ID: 19781947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The structure of a glycogen phosphorylase glucopyranose spirohydantoin complex at 1.8 A resolution and 100 K: the role of the water structure and its contribution to binding.
    Gregoriou M; Noble ME; Watson KA; Garman EF; Krulle TM; de la Fuente C; Fleet GW; Oikonomakos NG; Johnson LN
    Protein Sci; 1998 Apr; 7(4):915-27. PubMed ID: 9568898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetyl-beta-D-glucopyranosylamine: a potent T-state inhibitor of glycogen phosphorylase. A comparison with alpha-D-glucose.
    Oikonomakos NG; Kontou M; Zographos SE; Watson KA; Johnson LN; Bichard CJ; Fleet GW; Acharya KR
    Protein Sci; 1995 Dec; 4(12):2469-77. PubMed ID: 8580837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3'-axial CH2 OH substitution on glucopyranose does not increase glycogen phosphorylase inhibitory potency. QM/MM-PBSA calculations suggest why.
    Manta S; Xipnitou A; Kiritsis C; Kantsadi AL; Hayes JM; Skamnaki VT; Lamprakis C; Kontou M; Zoumpoulakis P; Zographos SE; Leonidas DD; Komiotis D
    Chem Biol Drug Des; 2012 May; 79(5):663-73. PubMed ID: 22296957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycogen phosphorylase as a target for type 2 diabetes: synthetic, biochemical, structural and computational evaluation of novel N-acyl-N´-(β-D-glucopyranosyl) urea inhibitors.
    Kantsadi AL; Parmenopoulou V; Bakalov DN; Snelgrove L; Stravodimos GA; Chatzileontiadou DS; Manta S; Panagiotopoulou A; Hayes JM; Komiotis D; Leonidas DD
    Curr Top Med Chem; 2015; 15(23):2373-89. PubMed ID: 26088352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.